Mangalam Drugs & Organics Ltd
Mangalam Drugs & Organics Ltd (MANGALAM) last reported results for the quarter ended Jun 2026, with sales of ₹57.12 crore and net profit of ₹-7.64 crore. The next scheduled event is a record date on 25 Oct 2026. The stock last traded at ₹29.7, a market capitalisation of ₹47.1 crore. Over the past 52 weeks the stock has ranged between ₹22.7 and ₹74. Figures are as of 6 Oct 2026 and are not real time.
Mangalam Drugs & Organics Ltd share price and key metrics
- Current price
- ₹29.7
- Market cap
- ₹47.1 cr
- Book value
- ₹65.1
- ROE
- -35.2%
- ROCE
- -14.3%
- Dividend yield
- 0.00%
- 52w high / low
- 74.0/22.7
Metrics as of 6 Oct 2026. Not real time.
Track Mangalam Drugs & Organics Ltd
Cruxal reads every Mangalam Drugs & Organics Ltd filing as it lands, scores what it means for the stock, and emails you the ones that matter. Free to start.
Mangalam Drugs & Organics Ltd growth and returns
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- -22%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- %
- TTM
- -292%
- 10 Years
- -16%
- 5 Years
- -27%
- 3 Years
- -34%
- 1 Year
- -60%
- 10 Years
- %
- 5 Years
- %
- 3 Years
- -12%
- Last Year
- -35%
Mangalam Drugs & Organics Ltd quarterly results
In the quarter ended Jun 2026, sales were ₹57.12 cr, down 0.2% from ₹57.21 cr a year earlier. Net profit was ₹-7.64 cr, up 44.6% year on year.
| ₹ crore | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Sales | 79.94 | 88.71 | 72.78 | 57.21 | 49.54 | 58.38 | 67.29 | 57.12 |
| Expenses | 71.24 | 79.94 | 62.88 | 61.83 | 52.38 | 59.92 | 72.91 | 56.21 |
| Operating profit | 8.7 | 8.77 | 9.9 | -4.62 | -2.84 | -1.54 | -5.62 | 0.91 |
| OPM % | 10.88% | 9.89% | 13.60% | -8.08% | -5.73% | -2.64% | -8.35% | 1.59% |
| Other income | 0.14 | 0.14 | 0.47 | 0.14 | 0.03 | 0.22 | 0.09 | 0.11 |
| Interest | 3.67 | 3.49 | 4.03 | 4.04 | 5.03 | 4.05 | 3.08 | 3.68 |
| Depreciation | 3.97 | 4.05 | 4.7 | 4.48 | 4.63 | 4.46 | 4.66 | 4.09 |
| Profit before tax | 1.2 | 1.37 | 1.64 | -13 | -12.47 | -9.83 | -13.27 | -6.75 |
| Tax % | -124.17% | 5.84% | 95.73% | 6.15% | -41.06% | 0.00% | 1.13% | 13.19% |
| Net profit | 2.69 | 1.29 | 0.06 | -13.8 | -7.35 | -9.84 | -13.42 | -7.64 |
| EPS (₹) | 1.70 | 0.82 | 0.04 | -8.72 | -4.64 | -6.22 | -8.48 | -4.83 |
Consolidated figures as reported by the company. Percentages are as published; totals may not sum exactly.
Mangalam Drugs & Organics Ltd annual results
| ₹ crore | Mar 2024 | Mar 2025 | Mar 2026 | TTM |
|---|---|---|---|---|
| Sales | 369 | 318 | 232 | 232 |
| Operating profit | 17 | 36 | -15 | -9 |
| OPM % | 4.7% | 11% | -6% | -3.9% |
| Net profit | -9 | 7 | -44 | -38 |
| EPS (₹) | -5.73 | 4.25 | -28.05 | -24.17 |
TTM is the trailing twelve months to the most recent quarter.
Mangalam Drugs & Organics Ltd balance sheet
| ₹ crore | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Equity capital | 16 | 16 | 16 |
| Reserves | 120 | 133 | 87 |
| Borrowings | 107 | 96 | 105 |
| Other liabilities | 91 | 121 | 106 |
| Total liabilities | 334 | 366 | 315 |
| Fixed assets | 148 | 163 | 159 |
| CWIP | 8 | 3 | 0 |
| Investments | 0 | 0 | 0 |
| Other assets | 178 | 201 | 156 |
| Total assets | 334 | 366 | 315 |
As reported by the company. Total assets equal total liabilities by construction.
Mangalam Drugs & Organics Ltd cash flow
| ₹ crore | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| Cash from operations | 4 | 43 | 4 |
| Cash from investing | -12 | -19 | -12 |
| Cash from financing | 5 | -22 | 6 |
| Net cash flow | -3 | 1 | -2 |
| Free cash flow | -8 | 23 | -8 |
| CFO / operating profit | 23% | 118% | -30% |
Negative figures are outflows. CFO / operating profit is a ratio, not an amount.
Mangalam Drugs & Organics Ltd operating ratios
| Per year | Mar 2024 | Mar 2025 | Mar 2026 |
|---|---|---|---|
| ROCE % | — | 8% | -14% |
| Debtor days | 28 | 45 | 63 |
| Inventory days | 185 | 303 | 239 |
| Days payable | 99 | 199 | 177 |
| Cash conversion cycle | 113 | 149 | 126 |
| Working capital days | 11 | 5 | -65 |
Ratios as computed by the source from the reported statements. Rows a company does not report are omitted.
Mangalam Drugs & Organics Ltd shareholding pattern
Promoters held 35.65% at Jun 2026, down from 50.30% at Jun 2025. FIIs 0.11%.
| % held | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Promoters | 50.30% | 50.30% | 50.30% | 50.30% | 50.30% | 35.64% | 35.65% | 35.65% |
| FIIs | 0.11% | 0.11% | 0.47% | 0.53% | 0.11% | 0.13% | 0.32% | 0.11% |
| Public | 49.58% | 49.58% | 49.23% | 49.16% | 49.57% | 64.22% | 64.03% | 64.24% |
| No. of shareholders | 19,508 | 19,679 | 19,697 | 19,728 | 19,881 | 21,227 | 25,140 | 24,465 |
As disclosed by the company to the exchanges. The last row is a count of shareholders, not a percentage.
Upcoming Mangalam Drugs & Organics Ltd events
The next scheduled event is a record date on 25 Oct 2026.
- Record dateDispatch of Postal Ballot/E-voting for shareholder approval
- Board meetingApproval of appointment of Shri Prabhakar Raghunath Zavar as Independent Director for 5-year term
See the full results calendar for every Indian company reporting in the next 30 days.
Mangalam Drugs & Organics Ltd corporate filings
- Intimation of Certificate received from RTA i.e. MUFG Intime India Private Limited under Regulation 74(5) of DP, 2018 for the quarter ended September 30, 2026Company Updatelow impact
- Mangalam Drugs and Organics Limited announces postal ballot notice, no immediate financial or strategic change disclosedCompany Updatelow impact
Cruxal's analysis: Mangalam Drugs and Organics Limited has issued a newspaper advertisement on October 2…
Read the full analysis - Mangalam Drugs and Organics Limited Seeks Shareholder Approval for Appointment of 78-Year-Old Independent Director via Postal BallotAGM/EGMmedium impact
Cruxal's analysis: Mangalam Drugs and Organics Limited has announced a postal ballot to seek shareholder…
Read the full analysis - Mangalam Drugs and Organics Limited confirms non-applicability of Large Corporate framework for FY 2026Otherslow impact
Cruxal's analysis: Mangalam Drugs and Organics Limited has formally declared that it does not fall under the…
Read the full analysis - Intimation for Closure of Trading Window pursuant to SEBI (Prohibition of Insider Trading)Regulations, 2015 for the quarter ended September 30, 2026Insider Trading / SASTlow impact
- Mangalam Drugs and Organics Limited Announces Appointment of New Statutory and Secretarial AuditorsCompany Updatelow impact
Cruxal's analysis: Mangalam Drugs and Organics Limited has formally announced the appointment of M/s S.N…
Read the full analysis - Mangalam Drugs and Organics Limited Announces Voting Results of 53rd Annual General MeetingAGM/EGMlow impact
Cruxal's analysis: Mangalam Drugs and Organics Limited has successfully concluded its 53rd Annual General…
Read the full analysis - Mangalam Drugs and Organics Limited concludes 53rd Annual General Meeting; appoints new statutory auditorsAGM/EGMlow impact
Cruxal's analysis: Mangalam Drugs and Organics Limited has successfully concluded its 53rd Annual General…
Read the full analysis - Mangalam Drugs & Organics Ltd discloses ongoing bank default status under LODR regulationsOthersmedium impact
Cruxal's analysis: Mangalam Drugs & Organics has issued a subsequent disclosure regarding its ongoing bank…
Read the full analysis - Mangalam Drugs and Organics Limited appoints Mr. Prabhakar Raghunath Zavar as Independent DirectorBoard Meetinglow impact
Cruxal's analysis: Mangalam Drugs and Organics Limited has announced the appointment of Mr. Prabhakar…
Read the full analysis - Mangalam Drugs & Organics Ltd schedules 53rd Annual General Meeting for September 23, 2026Company Updatelow impact
Cruxal's analysis: Mangalam Drugs & Organics Ltd has issued a newspaper publication regarding the notice of…
Read the full analysis - Mangalam Drugs & Organics Ltd schedules 53rd Annual General Meeting for September 23, 2026Otherslow impact
Cruxal's analysis: Mangalam Drugs & Organics Ltd has initiated the dispatch of its Annual Report for the…
Read the full analysis - Mangalam Drugs & Organics Limited Announces 53rd AGM and Releases Annual Report for FY 2025-26AGM/EGMhigh impact
Cruxal's analysis: Mangalam Drugs & Organics Limited has scheduled its 53rd Annual General Meeting for…
Read the full analysis - Mangalam Drugs & Organics Ltd reports subsequent default on financial obligationsOthersmedium impact
Cruxal's analysis: Mangalam Drugs & Organics Ltd has filed a disclosure regarding a subsequent default under…
Read the full analysis - Mangalam Drugs and Organics Limited Reports Significant Quarterly Loss for June 2026Company Updatehigh impact
Cruxal's analysis: Mangalam Drugs and Organics Limited has reported a sharp deterioration in financial…
Read the full analysis - Mangalam Drugs and Organics Limited Reports Continued Financial Losses for Quarter Ended June 30, 2026Board Meetinghigh impact
Cruxal's analysis: Mangalam Drugs and Organics Limited reported a standalone net loss of 7.55 crore for the…
Read the full analysis - Mangalam Drugs and Organics Limited announces resignation of Secretarial AuditorCompany Updatelow impact
Cruxal's analysis: Mangalam Drugs and Organics Limited has informed the stock exchanges that M/s. Ragini…
Read the full analysis - Mangalam Drugs and Organics Limited schedules Board Meeting for August 12, 2026, to consider Q1 FY27 financial results and auditor appointmentsBoard Meetinglow impact
Cruxal's analysis: Mangalam Drugs and Organics Limited has issued a formal intimation regarding a Board…
Read the full analysis
This page shows filings on a one-hour delay. Sign in to see them as they land, with Cruxal's analysis of what each one means.
Cruxal publishes market data and coverage for information only. Nothing here is investment advice.